| Quantity | 1Set | 50mg, 10mg, 100mg, 5mg, 25mg, 1mg | 10mg, 5mg, 50mg, 1mg, 25mg | 100µg, 10µg, 50µg, 1mg | 100µg, 10µg, 50µg, 1mg |
| Description | GALNT18 Human Pre-designed siRNA Set A contains three designed siRNAs for GALNT18 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components GALNT18 siRNA-1: 5 nmol (HPLC) GALNT18 siRNA-2: 5 nmol (HPLC) GALNT18 siRNA-3: 5 nmol (HPLC) siRNA GALNT18 Human Pre-designed siRNA Set A contains three designed siRNAs for GALNT18 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components GALNT18 siRNA-1: 5 nmol (HPLC) GALNT18 siRNA-2: 5 nmol (HPLC) GALNT18 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)... Read More | Inquire | Proteasome-activating peptide 1 TFA is a peptide and a potent proteasome activator. Proteasome-activating peptide 1 TFA increases the chymotrypsin-like proteasomal catalytic activity and, consequently, proteolytic rates both in vitro and in culture. Proteasome-activating peptide 1 TFA prevents Proteasome-activating peptide 1 TFA is a peptide and a potent proteasome activator. Proteasome-activating peptide 1 TFA increases the chymotrypsin-like proteasomal catalytic activity and, consequently, proteolytic rates both in vitro and in culture. Proteasome-activating peptide 1 TFA prevents protein aggregation in a cellular model of amyotrophic lateral sclerosis... Read More | Purity>95% (SDS-PAGE) Endotoxin level<1.0 EU/µgFunctionInhibits the synthesis of a number of cytokines, including IFN-gamma, IL-2, IL-3, TNF and GM-CSF produced by activated macrophages and by helper T-cells | Purity>97% by SDS-PAGE and HPLC analyses.Additional sequence informationN-terminal Glycine.FunctionChemotactic for monocytes and T-lymphocytes. Binds to CXCR3.Post-translationalCXCL10(1-73) is produced by proteolytic cleavage after secretion from keratinocytes |